| 영문 | sympathetic nervous system | 한글 | 교감신경계 |
|---|---|---|---|
| 설명 | 자율신경계의 일종으로 내장기능을 주로 항진시켜 활동을 증가시키는 기능을 가진다. 자율신경계의 다른 계열인 부교감신경계는 반대로 내장기능을 억제시켜 에너지를 비축하는 기능을 가진다. 자율신경계의 해부학적 특성은 신경이 중추신경계에서 나와 목표장기에 도달하기 전에 한번의 시냅스(synapse)를 이룬다는 점이며, 따라서 자율신경계는 두 개의 신경(시냅스를 이루기 전의 절전신경과 이룬 후의 절후신경)으로 구성된다. 자율신경계중 교감신경계는 중추신경계 즉 척수 부근의 교감신경절(sympathetic ganglion)에서 시냅스가 일어나고, 부교감 신경계는 중추신경계에서 멀리 떨어진 목표 장기부근의 신경절(ganglion)에서 시냅스가 일어나는 점이 다르다. |
||
| 영문 | musculoskeletal System | 한글 | 근골격계 |
|---|---|---|---|
| 설명 | 근육과 이들 근육이 붙어서 같이 활동을 수행하는 골격(뼈를 통털어 말함)을 함께 부르는 말. 따라서 여기의 근육은 모두 가로무늬근에 속하며, 수의적으로 움직일 수 있다. |
||
| 영문 | muscular system | 한글 | 근육계통 |
|---|---|---|---|
| 설명 | 근육에 의해 이루어진 하나의 계통을 임의적으로 나누어 부른 말. |
||
| 영문 | male reproductive system | 한글 | 남성생식기계 |
|---|---|---|---|
| 설명 | 남성의 생식기는 여러 기관으로 구성되어 있다. 고환, 부고환, 정관, 정낭, 전립샘, 외부성기(음경) 등으로 구성되는데, 실제적으로 정자를 생성하는 곳은 단 한 곳 고환뿐이며, 나머지 기관은 이를 돕는 기능을 수행하고 있다. 정자는 고환의 정세관이란 곳에서 만들어진 뒤에 밖으로 나와 긴 여정을 시작하게 된다. 그 뒤 부고환을 지나 좀 더 성숙해 진 뒤에 정관에서 정낭의 분비물과 만나고 다시 요도로 나가게 된다. 이때 요도 뒤쪽에 위치하는 전립샘의 분비물이 합쳐지게 되고 이 정액은 외부성기를 거쳐서 밖으로 나가게 된다.  |
||
| 영문 | lymphatic system | 한글 | 림프계 |
|---|---|---|---|
| 설명 | 대개 맥관계라고 하면, 혈관계와 림프관계를 합쳐서 말한다. 이중에 림프에 의해 이루어지는 하나의 계통이다. |
||
| VATER Associations | Vertebral defects Anal atresia Tracheo-Esophageal fistula ... |
|---|---|
| AEC | ankyloblepharon, ectodermal defects, and cleft lip [syndrome]; at earliest convenience; Atomic Energ... |
| ARBD | alcohol-related birth defects |
| CHILD | congenital hemidysplasia with ichthyosiform erythroderma and limb defects [syndrome] |
| MACDP | Metropolitan Atlanta Congenital Defects Program |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
|---|---|
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
| complement 1q | <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors. Chemical name: Complement C1q (12 Dec 1998) |
| complement 1r | <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage. Registry number: EC 3.4.21.41 (12 Dec 1998) |
| complement 1s | <enzyme> The activated form of complement 1 which has hydrolase activity. In the classical pathway, it splits first c4 and then c2 into active components, thereby generating a new enzyme referred to as eac142 or c42 or c3 convertase. Registry number: EC 3.4.21.42 (12 Dec 1998) |
| complement 2 | The third component in the complement reaction sequence. It is a beta-globulin with a molecular weight of 117,000, a serum concentration of 30 micrograms/ml and a sedimentation coefficient of 4. It activates c3. (12 Dec 1998) |
| complement 3 | The fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5, a molecular weight of 185,000 and a serum concentration of 1.3 micrograms/ml. Its fragments have anaphylatoxic, chemotactic, and histaminic action and affect smooth muscle. (12 Dec 1998) |
| complement 3a | <chemical> Smaller fragment formed when c3 convertase splits c3 into c3a and c3b. C3a is a 77-amino acid peptide that includes a carboxy-terminal arginine which is crucial for its biological activities. C3a causes symptoms of immediate hypersensitivity (anaphylaxis) including smooth muscle contraction, mast cell histamine release, and local inflammation. It is considered an anaphylatoxin along with c4a, c5a, and c5a des-arginine. Chemical name: Complement C3a (12 Dec 1998) |
| complement 3b | <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase. Chemical name: Complement C3b (12 Dec 1998) |
| complement 3b inactivators | Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop. (12 Dec 1998) |
| complement 3c | <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Chemical name: Complement C3c (12 Dec 1998) |
| complement 3 convertase | <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b. Registry number: EC 3.4.21.43 (12 Dec 1998) |
| complement 3d | <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g. Chemical name: Complement C3d (12 Dec 1998) |